Biopharmaceutical leader in the development of treatments for rare diseases
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to regulatory pathway for biosimilars and orphan drugs and opposing efforts in the President's Budget to alter that pathway.
S. 2236: Advancing Breakthrough Therapies for  Patients Act.
Development of reauthorizing legislation implementing the Prescription Drug User Fee Act (PDUFA) and related issues. H.R. 4132: Faster Access to Specialized Treatments Act.
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system. Monitored H.R. 3630: Temporary Payroll Tax Cut Continuation Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX